Figure 5
Suppression of SOX2 expression in primary HNSCC stem cells decreases antitumour drug resistance related to ABCG2. (A) Cell viability assay of cisplatin in control- and SOX2-overexpressing HNSCC cells. (B) Cell viability was determined after cisplatin treatment in control and shSOX2-transfected HNSCC stem-like cells. Treatments were performed in a dose-dependent manner (0–50 μ M, for 24 h, n=3). (C) Expression levels of ABCG2 in HNSCC stem-like cells transfected with scrambled siRNA and in HNSCC stem-like cells transfected with shSOX2; confirmed by western blot analysis. (D) The protein level of ABCG2 after transfection of ABCG2-siRNA into HNSCC stem-like cells. (E) Cell viability determined after cisplatin treatment in HNSCC stem-like cells transfected with scrambled siRNA and in HNSCC stem-like cells transfected with siABCG2 (n=3).
